Advertisement
New Zealand markets closed

  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     

  • NZD/USD

    0.6144
    -0.0027 (-0.43%)
     

  • NZD/EUR

    0.5733
    -0.0008 (-0.14%)
     

  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     

  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     

  • OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD

    2,348.40
    +30.40 (+1.31%)
     

  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • NZD/JPY

    96.6520
    -0.1680 (-0.17%)
     

Esperion to Participate in Upcoming June Investor Conferences

Esperion Therapeutics, Inc.
·1-min read
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.

Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET.

Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET.

Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

ADVERTISEMENT

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
investorrelations@esperion.com

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438